The therapeutic effect of the combined kallidinogenase and valsartan on early stage of type 2 diabetic nephropathy

Objective To observe the therapeutic effect of the combined kallidinogenase and valsartan on early stage of type 2 diabetic nephropathy.Methods The 90 study subjects were randomly divided into three groups of observation group(valsartan plus kallidinagenase,n = 30),ARB group (valsartan,n =30)and control group(n = 30).After 6 months of treatments the patients underwent examinations of urinary albumin excretion rate(UAER),urineβ2-microglobulin(β2-MG),mean arterial blood pressure(MAP),serum creatinine(Scr) and hemoglobin Ale(HbA_1c).Results The values of UAER andβ2-MG had obviously decrease after treatment and were lower in observation and ARB group than was control group(P0.01) and were lower in observation than in ARB group.The MAP of the three groups significantly decreased as compared to the baseline,with no differences among three groups (P0.05).Conclusion The combined valsartan and kallidinogenase treatment have good effects in the treatment of early stage of type 2 diabetic nephropathy with lessening the abnormal urinary albumin.